These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3347279)

  • 41. [Resistance to rHuEPO].
    Sułowicz W
    Przegl Lek; 1995; 52(3):88-9. PubMed ID: 7644681
    [No Abstract]   [Full Text] [Related]  

  • 42. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
    J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 44. [Erythropoietin in human pathology].
    Boivin P; Fauvert R
    Pathol Biol; 1967; 15(11):677-85. PubMed ID: 4860745
    [No Abstract]   [Full Text] [Related]  

  • 45. [Erythropoietin].
    Pavlović-Kentera V
    Srp Arh Celok Lek; 1989; 117(9-10):643-8. PubMed ID: 18709763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The efficacy of an erythropoietin-calcitriol combination in patients with chronic kidney failure on programmed hemodialysis].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kukhtevich AV
    Ter Arkh; 1995; 67(5):27-31. PubMed ID: 7638771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 48. [Human recombinant erythropoietin in treatment of uremic anemia in children with continual ambulatory peritoneal dialysis].
    Litwin M; Boguszewska-Baczkowska A; Jelonek A
    Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):135-6. PubMed ID: 8090665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of recombinant human erythropoietin on mean corpuscular volume in patients with the anemia of chronic renal failure.
    Schwartz AB; Orquiza CS
    Clin Nephrol; 1995 Apr; 43(4):256-9. PubMed ID: 7606880
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of erythropoietin on strength and functional status of patients on hemodialysis.
    Guthrie M; Cardenas D; Eschbach JW; Haley NR; Robertson HT; Evans RW
    Clin Nephrol; 1993 Feb; 39(2):97-102. PubMed ID: 8448925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recombinant human erythropoietin use in hemolytic anemia due to prosthetic heart valves: a promising treatment.
    Hirawat S; Lichtman SM; Allen SL
    Am J Hematol; 2001 Mar; 66(3):224-6. PubMed ID: 11279631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Individual differences in the efficacy of Recormon in patients with terminal kidney failure. The role of iron deficiency].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kondakhchan MA; Rogov VA; Trofimova EI
    Ter Arkh; 1993; 65(6):45-8. PubMed ID: 8378849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical application of erythropoietin].
    Urabe A
    Tanpakushitsu Kakusan Koso; 1991 May; 36(7):1473-8. PubMed ID: 1871370
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of recombinant human erythropoietin on soluble interleukin 2 receptor (SIL-2R) levels in haemodialysis patients.
    Altun B; Erdem Y; Haznedaroğlu I; Gürsoy M; Yasavul U; Turgan C; Cağlar S; Kirazli S
    Nephrol Dial Transplant; 1995 Nov; 10(11):2164. PubMed ID: 8643199
    [No Abstract]   [Full Text] [Related]  

  • 55. Improvement in anaemia following renal transplantation but not after erythropoietin therapy in a patient with sickle-cell disease.
    Thuraisingham RC; Roger SD; Macdougall IC; Cavill I; Stephens AD; Baker LR; Raine AE
    Nephrol Dial Transplant; 1993; 8(4):371-2. PubMed ID: 8390015
    [No Abstract]   [Full Text] [Related]  

  • 56. Recombinant erythropoietin: does it really effect sensitization?
    Phelan DL; Hibbett S; Wetter L; Hanto DW; Mohanakumar T
    Transplant Proc; 1991 Feb; 23(1 Pt 1):409-10. PubMed ID: 1990569
    [No Abstract]   [Full Text] [Related]  

  • 57. Recombinant human erythropoietin therapy: an overall approach to the anemia of chronic renal failure. Proceedings of symposia. December 11-13, 1988, San Antonio, Texas.
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):1-25. PubMed ID: 2757024
    [No Abstract]   [Full Text] [Related]  

  • 58. Erythropoietin.
    Johnson GR
    Br Med Bull; 1989 Apr; 45(2):506-14. PubMed ID: 2688815
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Hypertensive crisis in a female patient on a prolonged hemodialysis program treated with erythropoietin for nephrogenic anemia].
    Syzdół P; Baczyński D; Wańkowicz Z
    Pol Arch Med Wewn; 1996 Feb; 95(2):142-4. PubMed ID: 8677208
    [No Abstract]   [Full Text] [Related]  

  • 60. Erythropoietin.
    Lancet; 1987 Apr; 1(8536):781-2. PubMed ID: 2882187
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.